May 13, 2014 Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX) a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, announced its financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, Auspex reported a net loss of $10.1 million versus a net loss of $2.3 million in the comparable period in 2013. The increase in the net loss was largely a result of increased development activities for SD-809, higher general and administrative costs incurred as a public company, and a $3.6 million one-time, non-cash charge for the fair value of preferred stock warrants liability upon the completion of our IPO. Auspex Pharmaceuticals Inc (NASDAQ:ASPX) weekly performance is -2.07%. On last trading day company shares ended up $20.82. Analysts mean target price for the company is $38.75. Auspex Pharmaceuticals Inc (NASDAQ:ASPX) distance from 50-day simple moving average (SMA50) is -5.75%.
Advaxis Inc (NASDAQ:ADXS)‘s stock had its “outperform” rating restated byZacks in a research report issued on Tuesday. They currently have a $10.00 price objective on the stock. Zacks‘s target price points to a potential upside of 189.86% from the stock’s previous close. Advaxis, Inc. (NASDAQ:ADXS) shares fell -5.51 % in last trading session and ended the day on $3.26. Gross its return on assets is -154.60%. Advaxis, Inc. (NASDAQ:ADXS) quarterly performance is -30.79%.
June 2, 2014, Oncothyreon Inc. (USA) (NASDAQ:ONTY) announced the presentation of data from a Phase 1 trial of ONT-10, an antigen-specific immunotherapy targeting MUC1, at the American Association of Clinical Oncology (ASCO) 2014 Annual Meeting in Chicago. The data demonstrated that ONT-10 was well tolerated in this trial, resulted in a humoral immune response in the majority of patients and led to encouraging disease control in advanced stage patients with a variety of cancer types. Oncothyreon Inc (USA) (NASDAQ:ONTY) was closed at $3.26, while trading in range of $3.02 – $3.28. Oncothyreon Inc (USA) (NASDAQ:ONTY) year to date (YTD) performance is 75.00%.
On May 16, 2014, Organovo Holdings, Inc. (NYSEMKT:ONVO) announced that in response to investor inquiries it has updated the “Investor” section of its website, including the section titled “Investor FAQ” located at http://www.organovo.com/investors/frequently-asked-questions. Organovo Holdings Inc (NYSEMKT:ONVO) ended the last trading day at $7.28 . Company weekly volatility is calculated as 5.44% and price to cash ratio as 11.37. Organovo Holdings Inc (NYSEMKT:ONVO) showed a positive weekly performance of -1.22%.
The 2014 annual meeting of stockholders of Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) was held on May 28, 2014. At the 2014 annual meeting of stockholders, the Company’s stockholders voted on the following matters as described in the Company’s proxy materials: (1) the election of three directors, each for a one-year term expiring at the Company’s next annual meeting of stockholders and until such director’s successor is elected and qualified, (2) the ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014 and (3) the approval, on an advisory basis, of the compensation of the Company’s named executive officers. A total of 39,040,607 shares of common stock were present or represented by proxy at the 2014 annual meeting of stockholders, representing approximately 88.5% of the total shares of common stock entitled to vote at the 2014 annual meeting of stockholders. Enzon Pharmaceuticals Inc (NASDAQ:ENZN) net profit margin is 73.00% and weekly performance is 24.14%. On last trading day company shares ended up $1.08. Analysts mean target price for the company is $14.00. Enzon Pharmaceuticals Inc (NASDAQ:ENZN) distance from 50-day simple moving average (SMA50) is 17.80%.